Emergent Biosolutions Inc (EBS)vsUnited Therapeutics Corporation (UTHR)
EBS
Emergent Biosolutions Inc
$8.01
-0.50%
HEALTHCARE · Cap: $430.14M
UTHR
United Therapeutics Corporation
$541.60
+1.84%
HEALTHCARE · Cap: $23.74B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 328% more annual revenue ($3.18B vs $742.90M). UTHR leads profitability with a 41.9% profit margin vs 7.1%. EBS appears more attractively valued with a PEG of 0.38. UTHR earns a higher WallStSmart Score of 67/100 (B-).
EBS
Buy55
out of 100
Grade: C
UTHR
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-74.5%
Fair Value
$6.32
Current Price
$8.01
$1.69 premium
Margin of Safety
+62.9%
Fair Value
$1282.02
Current Price
$541.60
$740.42 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 42 of every $100 in revenue as profit
Strong operational efficiency at 45.0%
Safe zone — low bankruptcy risk
Earnings expanding 24.5% YoY
Areas to Watch
Smaller company, higher risk/reward
7.1% margin — thin
Elevated debt levels
Revenue declined 23.6%
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : EBS
The strongest argument for EBS centers on PEG Ratio, P/E Ratio, Price/Book. PEG of 0.38 suggests the stock is reasonably priced for its growth.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 41.9% and operating margin at 45.0%.
Bear Case : EBS
The primary concerns for EBS are Market Cap, Profit Margin, Debt/Equity.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio.
Key Dynamics to Monitor
EBS profiles as a value stock while UTHR is a mature play — different risk/reward profiles.
EBS carries more volatility with a beta of 2.44 — expect wider price swings.
UTHR is growing revenue faster at 7.4% — sustainability is the question.
UTHR generates stronger free cash flow (173M), providing more financial flexibility.
Bottom Line
UTHR scores higher overall (67/100 vs 55/100), backed by strong 41.9% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Emergent Biosolutions Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Emergent BioSolutions Inc., a life sciences company, focuses on providing preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHT). The company is headquartered in Gaithersburg, Maryland.
United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?